Karriereverlauf von Fernando Doñate
Ehemalige bekannte Positionen von Fernando Doñate
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Attenuon, LLC | Corporate Officer/Principal | - | - |
Proacta, Inc.
 Proacta, Inc. BiotechnologyHealth Technology Proacta, Inc. develops drugs to treat cancer. It is developing a new generation of hypoxia-activated prodrug compounds to treat cancer. The firm’s lead product PR610, is a proprietary, hypoxia-activated prodrug with potential antineoplastic activity. The company was founded in 2001 by William A. Denny, Amato J. Giaccia, William Robert Wilson and Martin J. Brown and is headquartered in La Jolla, CA. | Technik-/Wissenschafts-/F&E-Leiter | 22.02.2010 | - |
| Corporate Officer/Principal | 01.03.2008 | 22.02.2010 |
Ausbildung von Fernando Doñate
| University of Missouri | Doctorate Degree |
| Universidad Complutense de Madrid | Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 4 |
| Spanien | 2 |
Operativ
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
Sektoral
| Consumer Services | 3 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Proacta, Inc.
Proacta, Inc. BiotechnologyHealth Technology Proacta, Inc. develops drugs to treat cancer. It is developing a new generation of hypoxia-activated prodrug compounds to treat cancer. The firm’s lead product PR610, is a proprietary, hypoxia-activated prodrug with potential antineoplastic activity. The company was founded in 2001 by William A. Denny, Amato J. Giaccia, William Robert Wilson and Martin J. Brown and is headquartered in La Jolla, CA. | Health Technology |
| Attenuon, LLC |
- Börse
- Insiders
- Fernando Doñate
- Erfahrung
